Iterum Therapeutics ( (ITRM) ) has shared an announcement.
On March 7, 2025, Iterum Therapeutics plc announced the appointment of Joseph J. Whalen to its Board of Directors, effective March 10, 2025. Mr. Whalen, with over 30 years of experience in the bio-pharmaceutical industry, will serve as a Class III director and join both the audit and compensation committees. His appointment ensures the company’s compliance with Nasdaq’s audit committee requirements. Additionally, David Kelly was appointed as Chairman of the Board, following the resignation of Ronald M. Hunt.
More about Iterum Therapeutics
YTD Price Performance: -24.59%
Average Trading Volume: 660,831
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $47.72M
For a thorough assessment of ITRM stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com